Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Harbour BioMed Secures China IND Approval for HBM7004 Bispecific Antibody in ...

19 August 2026 · By · Wire by Fusion42

Published

19 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at biopharmaapac.com →

◆ Verified

Fusion42 · 19 August 2026 · Fusion42 review

Harbour BioMed received regulatory clearance from China's NMPA to begin clinical trials of its HBM7004 bispecific antibody targeting advanced solid tumours, following prior FDA clearance, marking a key step in advancing immunotherapy options in China.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

China's nod to Harbour BioMed's bispecific antibody trial opens a tangible pathway into its vast oncology market for you. Move quickly to understand local trial design expectations and patient recruitment to capitalise on this regulatory momentum.

◆ Coverage

1 source · 19 Aug 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialnmpa-approvalbispecific-antibodycancer-immunotherapybiotech